Table 1.
Growth inhibitory effect of signal inhibitors in combination with anticancer drugs in two scirrhous gastric cancer cell lines
| Anticancer drug | OCUM‐2M | OCUM‐8 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Rapamycin (mTOR) | CCI‐779 (mTOR) | AR‐A014418 (GSK3β) | SB239063 (p38αβMAPK) | SU9516 (CDK) | Rapamycin (mTOR) | CCI‐779 (mTOR) | AR‐A014418 (GSK3β) | SB239063 (p38αβMAPK) | SU9516 (CDK) | |
| 5FU | Synergistic | Synergistic | – | – | Additive | Synergistic | Synergistic | – | – | Additive |
| PTX | – | – | – | – | – | Additive | Additive | – | – | Additive |
| OXA | Additive | – | Additive | Additive | – | – | – | – | – | – |
| SN38 | – | – | Additive | – | Additive | – | – | – | – | Additive |
| GEM | – | – | – | – | Additive | – | Additive | – | – | Additive |
–, antagonistic; 5FU, 5‐fluorouracil; CDK, cyclin‐dependent kinase; GEM, gemcitabine; GSK, glycogen synthase kinase; mTOR, mammalian target of rapamycin; OXA, oxaliplatin; PTX, paclitaxel; SN38, irinotecan.